Pharma Focus Asia

Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301

Wednesday, May 24, 2023

Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RP-L301, the investigational lentiviral-based gene therapy for Pyruvate Kinase Deficiency (PKD), a rare blood disorder characterised by severe anaemia and excessive red blood cell breakdown.

Results from the RP-L301 programme demonstrated robust efficacy in both adult patients for up to 30 months post-infusion demonstrated by normalised haemoglobin (from baseline levels in the 7.0-7.5 g/dL range), improved haemolysis parameters, red blood cell transfusion independence and improved quality of life with documented improvements via formal quality of life assessments. 

Receiving RMAT designation from the FDA for RP-L301 is a major achievement to bring the first potentially curative gene therapy treatment to patients living with PKD who have high unmet need.

Pyruvate Kinase Deficiency (PKD) is a rare, monogenic red blood cell disorder resulting from a mutation in the PKLR gene encoding for the pyruvate kinase enzyme, a key component of the red blood cell glycolytic pathway. Patients with PKD have a high unmet medical need, as currently available treatments include splenectomy and red blood cell transfusions, which are associated with immune defects and chronic iron overload.
 

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference